define the binding site of the stem cell factor.
Polypeptide growth factors control cell proliferation and differentiation by binding to specific cell surface receptors. The stem cell factor (SCF) or mast cell growth factor (also called Kit ligand and Steel factor) is such a ligand that has been recently identified and molecularly cloned (1, 7, 8, 13, 22, 34, 39) . SCF is encoded by the well-studied Steel locus of the mouse (7, 13, 38) , and mutations within this gene cause a defective microenvironment for the development of melanocytes, germ cells, and certain hematopoietic progenitor cells (2, 27, 30) . Besides its functions in vivo in hematopoiesis, melanogenesis, and gametogenesis, SCF synergizes in vitro with other lymphokines to increase the number and the size of colonies of hematopoietic progenitors (3) .
The cell membrane receptor for SCF is a 145-kDa glycoprotein that spans the plasma membrane and carries a cytoplasm-facing tyrosine kinase activity (26, 35) . This receptor tyrosine kinase is encoded by the proto-oncogene c-kit, the cellular counterpart of the oncogene v-kit of the Hardy-Zuckerman 4 feline sarcoma virus (4) . c-kit is allelic with the dominant Wite spotting (W) locus on mouse chromosome 5 (6, 9) . The phenotype of W mutant mice is almost identical to that of Steel mutants, but various mutations vary in their effects on different cell lineages. The Kit protein shares structural architecture and sequence homology with the receptors for the platelet-derived growth factors (PDGFs) and the receptor for colony-stimulating factor 1 (36) . The similarity includes a common structure of the extracellular ligand binding domains of this group of receptors, which include five immunoglobulin (Ig)-like domains. The compact structure of the Ig-like structural unit is ex-SCF BINDING SITE 2225 of the interkinase domain (Ab 213) of the receptor. Anti-Kit monoclonal antibodies (MAbs) were obtained by injecting mice with a recombinant ectodomain of human Kit (20) . Hybridomas producing anti-Kit antibodies were selected as described previously (5) . Rabbit antibodies to phosphotyrosine were raised as described elsewhere (25) . Recombinant bacterially made SCF of human or rat origin was kindly provided by Amgen (Thousand Oaks, Calif.) . Protein A coupled to agarose was from Pharmacia (Uppsala, Sweden). Molecular weight standards for electrophoresis were from Sigma (St. Louis, Mo.), and radioactive materials were from Amersham (Amersham, Buckinghamshire, United Kingdom). Calf serum was purchased from HyClone (Logan, Utah). Unless otherwise indicated, all chemicals were from Sigma.
Constructions of human-mouse hybrid cDNA molecules. To construct MH-123 and HM-123 chimeric cDNAs, we introduced a new Kjpnl site in the intervening sequence between Ig-like domains 3 and 4 at homologous positions of both the human and the mouse c-kit cDNAs. The sequences of the synthetic oligonucleotides that were used in this site-directed mutagenesis were GACAYTTGCGGTACCAAAAG TAT (human) and ATACTI'T'IlGGTACCGCAAATGTCAC (mouse). The underlined bases represent mutations that changed serine (residue 298 in human Kit [35] ) to threonine in both receptors and thus enabled the introduction of the novel KpnI site. The chimeric cDNAs were constructed first in pBluescript (Stratagene) by digestion with KpnI and swapping of the corresponding fragments. After the orientation and reading frame of the fusion point were verified by nucleotide sequencing, the chimeric cDNAs were subcloned into the pLSV mammalian expression vector either in an XbaI site (MH-123) or in XhoI and XbaI sites (HM-123).
To construct hybrid cDNA molecules that encode MH-23, MH-12, MH-1, MH-2, and MH-3, we made use of the mutated human and mouse cDNAs that contained the novel KpnI site. In addition, we took advantage of a HindIll site that lies between the first and second Ig-like domains of human Kit, and also an EcoRI site that is localized in the region between domains 2 and 3. These endonuclease restriction sites were introduced into the homologous portions of the murine cDNA by using site-directed mutagenesis and three synthetic oligonucleotides that were annealed simultaneously with the cDNA. Establishment of stably expressing cell lines. The HSR cell line was established by cotransfection of pLSV/human c-kit and pSV2neo into NIH 3T3 cells by using the calcium phosphate precipitation method as described previously (32) . Gentamicin (G418; 1 mg/ml; GIBCO-BRL, Bethesda, Md.) was used to select colonies of cells that were resistant to neomycin. Immunoprecipitation analysis of Kit was used to select an overexpressing clone. To establish cell lines that express the chimeric receptors, we used NIH 3T3 fibroblasts and cotransfection of the chimeric cDNA of interest (in the pLSV expression vector) together with either pSV2neo or pSV2hph. The latter confers resistance to hygromycin. Transfectants were selected for growth in medium that contained gentamicin (1 mg/ml) or hygromycin (50 ,ug/ml).
The MK-37 cell line that overexpresses mouse Kit was established as described previously (21) . All cell lines were cultured in Dulbecco's modified Eagle medium supplemented with 10% bovine serum (HyClone).
Immunoprecipitation and Western immunoblot analyses.
Confluent cells grown in 10-cm-diameter dishes were washed once with phosphate-buffered saline (PBS), scraped into 1 ml of lysis buffer [20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES; pH 7.5), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM ethylenebis(oxyethylenenitrilo)tetraacetic acid (EGTA), 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 1 p,g of aprotinin per ml, 1 ,ug of leupeptin per ml], and incubated on ice for 5 min. After clearing of the cell lysates by centrifugation (12,000 x g, 15 min at 4°C), the Kit receptor was immunoprecipitated by using protein A-agarose beads that were precoupled to specific antibodies as indicated. Following 90 min of shaking at 4°C, the immunobeads were washed three times with HNTG (20 mM HEPES [pH 7.5], 150 mM NaCl, 10% glycerol, 0.1% Triton X-100), boiled in gel sample buffer, and separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) . In some experiments, the gel-embedded proteins were electrophoretically transferred onto nitrocellulose. The blot was then blocked with Tris-buffered saline (10 mM Tris [pH 7.4], 150 mM NaCl) that contained 10% low-fat milk and 1% ovalbumin. Antisera or purified MAbs were then added in the same solution, and incubation was carried out for 1 h at 22°C. For detection, the filters were washed three times (5 min each wash) with Tris-buffered saline-0.05% Tween 20 and reacted for 45 min at room temperature with horseradish peroxidase-conjugated protein A. The enzyme was removed by washing as described above, and the filters were reacted for 1 min with a chemiluminescence reagent (ECL; Amersham) and exposed to autoradiography film for 1 to 15 min. Analysis of Kit tyrosine phosphorylation following stimulation with SCF was performed exactly as described previously (19 
RESULTS
We have previously reported that the human SCF binds with high affinity to the human Kit receptor (Kd=-0.5 nM) but it does not detectably recognize murine Kit (21) . By contrast, the affinity of the rat SCF is significantly higher to murine Kit (Kd=-3 nM) than to the human protein (Kd=-50 nM [21] ). On the basis of this species-specific recognition of SCF, we envisioned that it would be possible to confine the binding site of the human SCF by replacing specific portions of human Kit with the corresponding portions of the murine receptor. In doing so, we were aided by the use of a battery of MAbs to human Kit (5) and ACK-2 MAb to the mouse receptor (24 [26] ) or the human receptor (serine 298 [35] ) had relatively small effects on the affinity to the rat or human SCF, respectively, and did not affect the tyrosine kinase activity of either receptor. The chimeric proteins are MH-123, a murine Kit protein in which the three N-terminal Ig-like domains were replaced by the corresponding domains of human Kit, and the reciprocal chimera HM-123 (Fig. 1A) . The cDNA hybrids were inserted into the pLSV mammalian expression vector (20) and were transfected into NIH 3T3 mouse fibroblasts. Individual clones of cells that overexpressed the chimeric proteins were then selected and expanded. We first analyzed the interaction of the expressed receptors with species-specific MAbs by performing immunoprecipitation with these antibodies and Western blotting of the complexes by using a polyclonal antibody to the cytoplasmic domain of Kit. As shown in Fig.  2A , HM-123 was recognized by the mouse-specific and ligand-inhibitory MAb ACK-2 (24) and also by two humanspecific MAbs that do not inhibit SCF binding (K94 [19] and K27 [5] (Fig. 2B) . To test the validity of the ligand cross-linking assays and also extend them to signal transduction, we analyzed the ability of the human and rat SCF to induce tyrosine phosphorylation of the chimeric proteins. Cells that overexpress each hybrid receptor were incubated for 10 min at 37°C with either human SCF (50 ng/ml) or rat SCF (150 ng/ml). Following cell lysis, the receptors were immunoprecipitated with antibodies to phosphotyrosine, and the immune complexes were electrophoresed and blotted with a rabbit antiserum to the cytoplasmic portion of Kit (Fig. 2C ). Whereas the tyrosine kinase of the HM-123 protein was stimulated by rat SCF, human SCF could not stimulate this kinase. However, the latter ligand efficiently activated the MH-123 receptor, indicating that this receptor has the same ligand specificity as does the wild-type human Kit. Taken together, results of the ligand cross-linking analysis (Fig. 2B ) and the tyrosine kinase assay (Fig. 2C) implied that the N-terminal three Ig-like domains of Kit confer to the receptor species-specific ligand binding and consequently also kinase activation by the respective ligand.
The qualitative functional equivalence of MH-123 and HM-123 proteins to the human and mouse receptors, respectively, was quantitatively confirmed by analysis of ligand displacement (Fig. 3) . In these assays, radiolabeled SCF was incubated, in the presence of increasing concentrations of unlabeled ligand, with cells that overexpress the various Kit proteins. Similar apparent affinities (Kd -3 nM) were displayed by the wild-type mouse Kit and the HM-123 chimera when rat SCF was tested (Fig. 3B) . The same ligand displayed an approximately 30-fold-lower affinity to either the human receptor or the MH-123 protein when its capacity to displace the radiolabeled human SCF was examined (Fig.  3C) . Similarly, the apparent affinities of the wild-type human Kit and the MH-123 protein to human SCF were practically identical ( Fig. 3A and Table 1 ). We therefore concluded that the three N-terminal Ig-like domains of the mouse and human Kit proteins contain all of the structural determinants needed for the species-specific binding of SCF.
Binding of SCF-competitive MAbs is conferred by pairs of Ig-like domains that include the second domain. To further confine the ligand binding site within the three N-terminal
Ig-like domains, we focused on the binding of the human SCF and constructed two chimeric proteins that separately included consecutive pairs of these structural units (Fig.1B) . Both proteins were derived from themurineKit, but they contained either the first and second human Ig-like domains (MH-12 protein) or the second and third human domains . A series of fourMAbs to human Kit was then used to immunoprecipitate the fusion proteins from cells that were transfected with the respective cDNA molecules. As shown in Fig. 4 To extend the immunological mapping of MAbs to the murine receptor, we examined the interaction of the chimeric receptors with the mouse-specific MAb ACK-2, which inhibits SCF binding to the murine receptor. Surprisingly, this antibody was able to immunoprecipitate the MH-1 and MH-12 proteins, indicating that its epitope is distal to the first two Ig-like loops (Fig. SC) . Consistent with this interpretation, the MH-2 and MH-3 proteins partially interacted with ACK-2, but the MH-23 protein exhibited no interaction with this MAb (Fig. SC) . We therefore concluded that the mouse-specific MAb recognized a site that lies within the intervening sequence between Ig-like domains 2 and 3. These results suggested that the SCF binding site resides in the second Ig-like domain of the human receptor, but the corresponding site of the rodent Kit may flank this domain at its carboxy-terminal side. However, considering the relative size of the ligand-competitory MAb and the SCF binding site, it is possible that the inhibitory effect of ACK-2 is due to steric hindrance. SCF binding analysis reveals complex interdomain interactions. Direct binding of radiolabeled SCF to the various chimeric proteins was assayed by using ligand displacement and Scatchard analyses; the results are summarized in Table  1 . Competition between unlabeled human SCF and the radiolabeled ligand showed that MH-23 and the wild-type human Kit displayed practically indistinguishable displacement curves (Fig. 6 ). An approximately twofold reduction in affinity was observed with the MH-2 protein, and the MH-12 chimera exhibited somewhat lower affinity to human SCF (Fig. 6 ). As predicted, both MH-1 and MH-3 recombinant receptors exhibited no detectable specific binding of the human SCF (data not shown). Saturation curves and Scatchard analysis of ligand binding (Fig. 7) almost precisely confirmed the binding constants and established the relative order of affinities of the recombinant receptors toward SCF. Furthermore, this analysis indicated the existence of apparent homogeneous populations of binding sites with all of the proteins that were examined (Fig. 7) . In summary, all of the chimeric mouse proteins that contained the second human Ig-like domain displayed a remarkable increase (400-to 800-fold) in affinity to human SCF ( Ig-like domain apparently imposed a small negative effect on binding of the human SCF. A chimeric mouse Kit that contains the second human Ig-like domain is a dual-specificity receptor. The observation that the chimeric receptor MH-12 was recognized by the mouse-specific and ligand-competitive MAb ACK-2 (Fig.  5C ), as well as by the human-specific antagonistic MAbs K44 and K57 (Fig. 4) (Fig. 6 and 7) without reducing the original affinity of the murine receptor to the rat SCF (Table 1) . By contrast, mouse chimeric proteins MH-3 and MH-23, which contained the third human Ig-like domain, practically lost their high affinity to rat SCF (Table 1) . We therefore concluded that the specificity for human SCF is associated with the second Ig-like domain, whereas the third murine domain is apparently essential for recognition of the rodent ligand. This conclusion is best exemplified by the fact that two chimeric receptors, MH-2 and MH-12, are dual-specificity receptors; that is, they recognized both the human and rat ligands with affinities that were comparable with those of the parental wild-type Kit proteins (Table 1) . Although this interpretation is consistent with the localization of the epitopes of the ligand-competitive MAbs (Fig. 5) , according to an alternative interpretation, the third human domain exerts a negative effect on binding of the rat SCF to mouse domain 2.
We next examined the extent of structural overlap between the binding sites of the mouse and human ligands by testing the ability of one of the dual-specificity receptors, MH-12, to simultaneously bind a radiolabeled ligand and a MAb that is inhibitory for binding of the other ligand. Covalent cross-linking of radiolabeled human SCF to MH-12 was found to abolish the interaction between this receptor and the mouse-specific MAb ACK-2 (Fig. 8) . Likewise, MH-12, which became covalently cross-linked to rat SCF, was not recognized by the human-specific MAb K44 (Fig. 8) . We therefore concluded that despite the dual ligand specificity of MH-12, the two binding sites are probably too close to one another to allow independent accessibility of a ligand and an antagonistic MAb that are directed to distinct sites. Whole cell lysates were prepared from 106 cells that overexpress MH-2. The lysates were subjected to immunoprecipitation (IP) with the indicated human-specific mAbs. The immunocomplexes were resolved by gel electrophoresis and analyzed by immunoblotting (IB) with a rabbit antiserum to Kit (Ab 212) as described in the legend to Fig. 2A. (C) Reactivities of the chimeric receptors with a mouse-specific mAb. Whole lysates from 106 cells that overexpress the indicated chimeras were subjected to immunoprecipitation (IP) with the mouse-specific MAb ACK-2, which competes with SCF for binding to Kit. The immunocomplexes were analyzed by immunoblotting (IB) with a polyclonal antibody (Ab 212) to Kit exactly as for panel B. radiolabeled human SCF to the MH-12 molecules but also inhibited 95% of the binding of the rat SCF to the same receptor. Likewise, the mouse-specific antibody ACK-2 had no effect on binding of the human SCF to the human receptor, but it inhibited 93 and 91%, respectively, of the binding of the rat SCF and the human ligand to MH-12 (data not shown).
DISCUSSION
The aim of this study was to molecularly confine the ligand binding site of the Kit/SCF receptor. To binding specificity. We further determined that the second domain of the human receptor is the primary determinant of specificity to the human ligand but the adjacent Ig-like units are also involved in ligand recognition. It appears, however, that the third, rather than the second, Ig-like domain of the mouse receptor provides the major contribution to ligand specificity. These two features of ligand binding to Kit, namely, the involvement of noncontiguous segments of the receptor and the apparent lack of structural coincidence of the specificity-determining sites of the human and rodent ligands, are schematically illustrated in a model shown in Fig. 9 and further discussed below. Perhaps the most unexpected observation of this study is the identification of two chimeric proteins, MH-12 and MH-2, as dual-specificity receptors and, on the other hand, the fact that neither the human nor the rodent ligand binds with high affinity to another receptor, MH-3 (Table 1 ). In analogy with the receptors for PDGFs, which appear to share ligand binding features with Kit, the a receptor, like MH-12, is a dualspecificity receptor for both PDGF-BB and PDGF-AA, whereas the ,B type of receptor is similar to MH-23 or wild-type Kit in that it binds only one ligand, PDGF-BB (12) .
Noncontiguous regions of the extracellular domain define ligand specificity. The three N-terminal Ig-like domains of Kit appear to determine ligand specificity, as revealed by domain swapping experiments ( Fig. 2 and 3) . Moreover, this portion of Kit is sufficient to confer high-affinity ligand binding to a soluble receptor that lacks the fourth and fifth domains (5) . However, within the ligand binding portion, each Ig-like domain appears to play a distinct role in SCF recognition. Thus, the second human domain is the major specificity determinant, as its presence in the mouse receptor is sufficient to confer high-affinity binding of the human SCF to the MH-2 chimeric receptor ( Fig. 6 and Table 1 ). In addition, human-specific MAbs that inhibit SCF binding were found to be directed against this domain (Fig. SB) . On the other hand, the third human Ig-like domain appears to exert an additive effect on the recognition of the human ligand. This conclusion was inferred from the higher ligand affinity of MH-23 than of MH-2 ( (Table 1) . Obviously, our biochemical approach cannot determine whether or not the effects of domains 1 and 3 are mediated by direct contact with the ligand or whether they reflect the existence of molecular constraints that indirectly determine the conformation of the ligand binding cleft. However, the identification of domain 2 of Kit as the primary determinant of binding of human SCF is consistent with its being highly immunogenic (Table 1 and Fig. 9 ). This finding is also reminiscent of the apparent localization of the binding site of PDGF-AA, by means of a deletion mutant, to the second domain of the ax-PDGF receptor (11 Ig-related sequences (33) , but it displays unique structural features that mark it as a nonclassical Ig-like loop. These features include the presence of two additional cysteine residues within the loop and the absence of several canonical residues of the Ig fold.
Our finding that noncontiguous receptor regions stabilize the SCF-Kit complexes are analogous to observations that were made with other growth factor receptors. For example, the binding of epidermal growth factor to its receptor involves mostly a sequence that connects the two cysteinerich domains, but the N-terminal region also contributes to the binding energy (17, 18) . Likewise, the binding pocket of insulin is defined by noncontiguous regions of the insulin receptor (10, 29 (Fig. SC) . Moreover, the MH-2 and MH-12 chimeric receptors that apparently contain the major sites for both the human ligand (domain 2) and the murine SCF (domain 3) indeed displayed high affinity to both ligands ( (Fig. 8) . We therefore concluded that the binding sites of the rodent and human SCF overlap to some extent (Fig. 9 ). This feature of the Kit/SCF receptor is analogous to other receptor tyrosine kinases. For instance, the Bek/FGFR2 receptor for fibroblast growth factors (FGFs) binds acidic as well as basic FGF apparently through different portions of its ectodomain, which contains three Ig-like units (23, 31, 37) . Similarly, distinct portions of the closely related receptors for insulin and insulin-like growth factor 1 mediate interaction with the corresponding ligands (16, 29) . Lastly, the binding sites of PDGF-AA and PDGF-BB on the ax-PDGF receptor are not structurally coincidental (11) . The studies that we described represent the first attempt to systematically address the structurefunction relationships within the five-lobe structure of the ectodomain of Kit. 
